Dr Marian Schini

MD, PhD, FHEA

Department of Oncology and Metabolism

Clinical Research Fellow

m.schini@sheffield.ac.uk
+44 114 215 9698

Full contact details

Dr Marian Schini
Department of Oncology and Metabolism
Metabolic Bone Centre Sorby Wing
Northern General Hospital
Herries Road
Sheffield
S5 7AU
Profile

For enquiries, please contact - om-operational@sheffield.ac.uk

I graduated from the Medical school of the University of Patras in Greece in 2005. After 4 years of training in Internal Medicine and 4 years in Endocrinology and Diabetes, I successfully obtained my CCT in Endocrinology and Diabetes in 2014. I have been working as a clinical research fellow for the University of Sheffield since 2015, with an interest in osteoporosis and calcium metabolism disorders. During this time, I undertook a PhD focusing on the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism, two disorders of calcium metabolism. This project was funded by The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing and the Osteoporosis 2000 Support Group.

After completing my PhD in 2020, I was appointed as an NHS consultant at the Metabolic Bone Centre at Sheffield Teaching Hospitals, but maintained my role as a fellow with the University of Sheffield, to pursue my research interest in bone metabolism further.

I have been involved in several research projects in collaboration with researchers from the University of Sheffield, national but also international higher institutions. These projects have led to a number of publications and awards. I am the primary investigator for the POSE study (PINP and Osteoporosis in Sheffield Evaluation), a project aiming to investigate the use of PINP to monitor osteoporosis treatment in clinical practice by non-specialist practitioners. I am also the lead investigator in studies evaluating current osteoporosis treatments further, like denosumab and zoledronic acid. I have supported and continue to support a number of clinical trials as both a primary and sub-investigator. Some of these studies are on rare disorders of bone metabolism like X-linked hypophosphataemia and osteogenesis imperfecta, for which I have developed a special interest.

Research interests

My research interests are osteoporosis, calcium metabolism disorders and rare bone metabolism disorders like X-linked hypophosphataemia and hypophosphatasia.

My PhD work was around the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism. This project provided some further understanding of these two newly described conditions which can help in their monitoring and treatment. Due to my interest and growing experience in these disorders, I was asked to assist in preparing the next international guidelines on normocalcaemic hyperparathyroidism

I was also involved in a number of systematic reviews and meta-analyses to evaluate the risk of fractures in patients with different chronic conditions like Parkinson’s disease and diabetes mellitus. These studies were performed in collaboration with ScHARR and the team of Dr Steve Cummings in the University of California.

Throughout the years, I provided support and continue to support various clinical trials around bone metabolism like:

  • Primary investigator in the clinical trial: ‘The BUR02 study: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)
  • Sub-investigator in the clinical trial “TOPaZ: Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid”
  • Sub-investigator in the clinical trial “The STAG Study: Phase II Study of the Impact of AZD4017, A Selective 11β-HSD1 Inhibitor, on Biochemical Markers of Bone Turnover in Post-Menopausal Osteopenia”
  • Sub-investigator in the clinical trial “AXLES: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)”
  • Sub-investigator in the “SeMS study: Double-blind, randomised, placebo-controlled trial on the effect of selenium supplementation on musculoskeletal health in older women”
Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Conference proceedings papers

  • Vilaca T, Schini M, Harnan S, Poku E, Cummings SR & Eastell R (2020) SUN-622 The risk of hip and non-vertebral fractures in diabetes : a systematic review and meta-analysis update. Journal of the Endocrine Society, Vol. 4(Supplement_1). San Francisco, CA, USA, 28 March 2020 - 31 March 2020. View this article in WRRO RIS download Bibtex download
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2018) NORMOCALCAEMIC HYPERPARATHYROIDISM: STUDY OF THE PREVALENCE AND NATURAL HISTORY IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 627-627) RIS download Bibtex download
  • Schini M & Eastell R (2018) ADULT HYPOPHOSPHATASIA: A DISEASE WHERE THE CLINICAL COMPLICATIONS COULD BE AVOIDED BY CAREFUL EVALUATION OF PATIENTS. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 632-633) View this article in WRRO RIS download Bibtex download
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2018) Normocalcaemic Hyperparathyroidism: Study Of The Prevalence And Natural History In A United Kingdom Referral Population. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 129-129) RIS download Bibtex download
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2016) NORMOCALCAEMIC HYPERPARATHYROIDISM: PREVALENCE IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp 649-650) RIS download Bibtex download
  • Manolakopoulos S, Schini M, Deutsch M, Triantos CK, Meal M, Striki A, Karafatelli M, Tzourmakliotis D & Papatheodoridis GV (2010) ABSOLUTE NEUTRIPHIL COUNT IS NOT ASSOCIATED WITH THE DEVELOPMENT OF INFECTIONS IN PATIENTS WITH HCV HEPATITIS RECEIVING ANTI VIRAL TREATMENT. HEPATOLOGY, Vol. 52(4) (pp 807A-807A) RIS download Bibtex download
Teaching interests

I am engaged in various teaching sessions for undergraduate and postgraduate students and have supervised a number of research placement students, including a CIMA MRes student and visiting clinical fellows.

Professional activities

I am a Fellow of the Higher Education Academy and a member of the Association of Medical Educators.

Current projects
  • The use of PINP in a primary care setting to monitor osteoporosis (the POSE Study)

This is a project that I lead on and involves the assessment of a bone marker called PINP in a real-life setting in order to check whether patients that are monitored using this marker have better outcomes in terms of bone density, number of fractures and treatment persistence than the patients not monitored. This project is in collaboration with ScHARR and Professor Bo Abrahamsen in Denmark and has received a grant funding by Roche Diagnostics.

  • Osteoclast precursors in patients treated with denosumab

Denosumab is an anti-osteoporotic medication that has proven effective in preventing bone loss and reducing the incidence of fractures. However, on discontinuation of denosumab there is a rebound of bone turnover to 200% of pre-treatment baseline, which is associated with loss of the comparative gains in bone strength, and concerns have arisen amid cases reporting an increase in the incidence of osteoporotic fractures. The aim of this project, is to investigate the effect of denosumab on the osteoclast precursor population in order to elucidate the cellular mechanisms of this phenomenon.

  • Neutrophil migratory function in patients treated with zoledronic acid

Both statins and zoledronic acid target the same metabolic pathway, therefore we suspect the mechanism underlying the reduction in morbidity and mortality in patients with zoledronic acid may be related to an ameliorated function of neutrophils. This is an early stage study, aiming to see what the effect of zoledronic acid is on the migratory function of neutrophils and their ability to engulf and destroy bacteria.